1. Research Objectives

Our laboratory, lead by Tada Taniguchi (Project Professor) and Hideyuki Yanai (Project Associate Professor), endeavors to better understand the fundamental mechanisms that underlie innate immune receptor signaling and gene expression, and how host-derived danger signals stimulate or suppress inflammatory responses. It also aims to contribute to the development of new methods and development of drugs for the prevention and treatment of inflammation-associated diseases, including autoimmunity and cancer. We provide below background of our laboratory and a description of its current projects.

2. Historical Background

Cytokines are soluble mediators of cell-to-cell communications that play critical roles in oncogenesis and immunity. Many cytokines are produced simultaneously, at very low levels and cooperate with each other to elicit diverse biological responses. This has made it difficult to study the contribution of a single cytokine to a given biological function. Therefore, the molecular isolation and consolidation of cytokines have made it possible to study each cytokine as a single molecule to elucidate their intracellular signaling pathways and gene regulation mechanisms. A majority of our laboratory’s research projects stem from the lab’s original discovery and molecular characterization of two human cytokine genes, human fibroblast interferon (renamed thereafter as IFN-β) and interleukin-2 (IL-2), that were made between the late 1970s and early 1980s (Proc. Jpn. Acad., 55B, 464-469, 1979; Gene, 10, 11-15, 1980; Nature, 302, 305-310, 1983). We also demonstrated, in collaboration with Dr. C. Weissmann’s group, that IFN-α and IFN-β genes constitute a gene family. These discoveries constitute the first discovery and recognition of a cytokine family, which are now referred to as Type I IFN genes (Nature, 285, 547-549, 1980). The importance of these discoveries are also highlighted by the fact that IFN-β and IL-2 are used in the clinic for the treatment of human diseases such as cancer, hepatitis, and autoimmune multiple sclerosis. One of the more immediate findings that followed this work was our characterization of the IL-2 receptor β chain, which demonstrated for the first time that non-catalytic activity in the cytoplasmic region is critical to transmit the cytokine signal by recruiting non-receptor type protein tyrosine kinases (Science, 244, 551-556, 1989; Cell, 59, 837-845, 1989; Science, 252, 1523-1528, 1991; Annu. Rev. Immunol., 11, 245-267, 1993; Science, 266, 1045-1047, 1994; Science, 268, 251-255, 1995). Further, during the course of our research on cytokine gene expression and signaling we discovered a new family of transcription factors called interferon regulatory factors (IRFs) (Cell, 54, 903-913, 1988; Cell, 58, 729-739, 1989; Ann. Rev. Immunol. 19, 623-655, 2001; Nature Reviews Immunology, 6, 644-659, 2006). We have since focused on elucidating the functions of these factors in the regulation of immunity and oncogenesis; our research on IRFs has led to the discovery of the general regulatory mechanism of the type I IFN gene induction involving IRF3 and IRF7 in cells infected by viruses (Immunity, 13, 539-548, 2000; Nature Rev. Mol. Cell Biology, 2, 378-386, 2001), and more recent work using gene disruption studies have validated this model of virus-induced, IFN signal-dependent amplification of IFN gene induction by these two transcription factors (Nature, 434, 772-777, 2005; Nature Reviews Immunology, 6, 644-659, 2006). Further, our studies on IRF proteins has resulted in the discovery of a novel link between IFNs and the p53 tumor suppressor gene (Science, 259, 968-971, 1993; Science, 259, 971-974, 1993; Ann. Rev. Immunol. 19, 623-655, 2001; Nature 424, 516-523, 2003). Firstly, we showed that IRF1 is involved in the regulation of apoptosis and, in cooperation with the tumor suppressor p53, regulates cell cycle arrest (Cell, 77, 829-839, 1994; Nature, 376, 596-599, 1995; Nature, 382, 816-818, 1996). Moreover, the loss of IRF1 exacerbated tumor development in p53-deficent mice (Genes. Dev. 12, 1240-1245, 1999). These studies, therefore, highlighted an interesting connection between immunity and oncogenesis (Oncoimmunology, 1, 1376-1386, 2012). While the core of our research was aimed at clarifying the function of IRF proteins in the context of immunity, the broad scope of our scientific interests now encompass a number of additional areas including those that pertain to innate immune system activation, inflammation, autoimmunity, and oncogenesis.

3. Ongoing Projects

We would like to note that our lab’s policy is to respect the scientific interests and ideas of all students and scientists in forging their research projects. We believe that each project has conceptual novelty with the potential to broadly impact the worldwide scientific community.

(1) HMGB1 in the regulation of inflammation and oncogenesis

The activation of innate immune responses mediated by the transmembrane Toll-like receptors (TLRs) and cytosolic receptors in response to nucleic acids is crucial to protective and pathological immunity. We have found that high-mobility group box (HMGB) proteins function as universal sentinels for nucleic acids for these pathways. HMGBs bind to all immunogenic nucleic acids and show a positive correlation between the affinity of the interaction and the immunogenic potential of the response. We showed that HMGB proteins are required for the activation of all nucleic acid-sensing receptors, i.e., cytosolic nucleic-acid-sensing receptors, TLR3, TLR7 and TLR9 by their cognate nucleic acids. Our results therefore indicated a hierarchy wherein the selective activation of nucleic-acid-sensing receptors is contingent on the more promiscuous sensing of nucleic acids by HMGBs (Nature, 462, 99-103, 2009). Although the innate immune system can discriminate between many forms self and non-self, nucleic acids themselves are common to host and infectious microbes. Thus, recognition of self versus non-self nucleic acids by innate receptors must be in a delicate balance, and any imbalance of this system may be closely linked to autoimmune and auto-inflammatory disorders. Indeed, there is ample evidence for a connection between nucleic-acid-mediated immune responses in animal models of autoimmune diseases and human diseases such as SLE. Hence, designing inhibitors that impede nucleic-acid-mediated immune responses might be a useful strategy to treat autoimmune diseases. Towards this aim, we developed an oligodeoxynucleotide (ODN), termed ISM ODN that shows very high binding affinity to HMGB proteins and yet does not evoke innate immune responses. We found that ISM ODN treatment in mice suppresses the development of experimental autoimmune encephalomyelitis (EAE), an autoimmune demyelinating disease model of human multiple sclerosis, in which nucleic-acid-sensing TLRs contribute to the development of the disease. Interestingly, ISM ODN treatment also blocks LPS-mediated death by endotoxin shock (Proc Natl Acad Sci U S A,108,11542-7, 2011), suggesting that ISM ODN also blocks HMGB1-mediated inflammatory responses. We also generated Hmgb1-floxed mice to achieve the conditional inactivation of the gene in a cell- and tissue-specific manner (Proc Natl Acad Sci U S A, 110, 20699-704, 2013). In these studies we observed that HMGB1, released by liver cells, is required for liver metastasis of tumor cells (unpublished). Thus, ISM ODN may have therapeutic potential for variety of disease conditions such as autoimmunity, sepsis and cancer metastasis. We are currently analyzing modifications of the extracellularly released HMGB1 to gain further mechanistic insight on how nuclear HMGB1 is released outside of a cell to evoke these varied immunoregulatory functions.

(2) Identification and characterization of self-derived molecules which regulate inflammation and immunity

Cellular components released into the external milieu as a result of cell death are generally termed damage-associated molecular patterns (DAMPs). Although DAMPs are conventionally thought to be protective to the host by evoking inflammatory responses, there is the prevailing notion that release of DAMPs can also underlie or exacerbate disease development. How resultant DAMP-mediated responses are regulated remained to be fully addressed. We identify prostaglandin E2 (PGE2) as a DAMP that negatively regulates immune responses. The production of PGE2 is augmented under cell death-inducing conditions via the transcriptional induction of the cyclooxygenase 2 (COX2) gene and that cell-released PGE2 suppresses the expression of genes associated with inflammation, thereby limiting the cell's immunostimulatory activities. Consistent with this, inhibition of the PGE2 synthesis pathway potentiates the inflammation induced by dying cells. We also provided in vivo evidence for a protective role of PGE2 released upon acetaminophen-induced liver injury as well as a pathogenic role for PGE2 during tumor cell growth (Proc Natl Acad Sci U S A.,113, 3844-9, 2016). Our study thus placed this classically known lipid mediator in an unprecedented context-that is, an inhibitory DAMP vis-a-vis activating DAMPs, which may have translational implications. We have then identified several self-derived molecules, which we believe are the genuine activating DAMPs; more detailed analysis is underway.

(3) The IRF family of transcription factors in the regulation of inflammation and immunity

Interferon regulatory factors (IRFs) constitute a family of transcription factors that commonly share a novel helix-turn-helix DNA-binding motif. Following the initial identification of two structurally related members, IRF-1 and IRF-2 in our laboratory, seven additional members have been reported. Their functional roles, through interactions with their own or other members of the family of transcription factors, are becoming clearer in the regulation of host defense, such as innate and adaptive immune responses and oncogenesis (Ann. Rev. Immunol., Vol. 19, 623-655, 2001;Nature Rev. Immunol., Vol. 6, 644-659, 2006). By generating mice deficient in either of these transcription factor genes, we adduced evidence for the essential role of IRF3 and IRF7 for the Type I IFN gene induction by the activation of innate receptors (Nature, Vol. 434, 772-777, 2005, Nature, Vol. 434, 1035-1040, 2005). In collaboration with Tak Mak and colleagues, we also showed there is a critical contribution of IRF5 in the induction of inflammatory cytokine genes (Nature, Vol. 434, 243-249, 2005). We recently generated Irf3-floxed mice to achieve the conditional inactivation of the gene in a cell- and tissue-specific manner. The analysis of these mice is in progress.

(4) Bacteriophage and intestinal inflammation

The intestinal microbiome is a dynamic system of interactions between the host and resident flora of microbes. Although a fine balance and mutually beneficial relationship is maintained under physiological conditions, imbalance in the ecosystem underlies the development and/or aggravation of disease such as inflammatory bowel disease. Our lab is interested in bacteriophages, which can infect intestinal bacteria and affect immunogenic potential or recognition by the host immune system, thereby contributing to intestinal diseases. In this context, we have isolated a new bacteriophage that, upon infection to a commensal bacterium in the intestine, potentiates inflammatory responses. Work is in progress to elucidate the mechanisms by which the phage infection potentiates the bacterium's immunogenicity and how this relates to development of intestinal inflammatory conditions. This work is a collaboration with Dr. Makoto Kuroda in National Institute of Infectious Diseases and Drs. Yasunori Tanji and Kazuhiko Miyanaga of Tokyo Institute of Technology.

(5) Inter-organ regulation of gut commensal bacteria for intestinal immune homeostasis

The composition of the gut commensal microbiota reflects the co-evolution of host and microbes to achieve intestinal homeostasis that is mutually beneficial. There has been much attention on how intestinal microbiota contributes to the regulation of the gut immune system, since its dysregulation underlies the development of inflammatory diseases in the intestine and other organs. We have recently discovered a unique example of how distant organ-derived immunomodulatory molecule critically shapes symbiotic status of intestinal bacteria. In particular, we have shown that surfactant protein D (SP-D), which to date has been exclusively studied for its role in the lung homeostasis is also produced in gallbladder and secreted into intestinal lumen. SP-D binds selectively to commensal bacteria, thereby interfering with their overgrowth to maintain symbiotic status in the intestine. Indeed, SP-D-deficient mice manifest intestinal dysbiosis, accompanied by an abnormal development of regulatory T cells, and are highly susceptible to the development of DSS-induced colitis. Thus, our study is revealing a unique inter-organ regulation of intestinal immune homeostasis by dynamic cross-talk between gallbladder and intestine via SP-D with clinical implications such as cholecystectomy. This work is a collaboration with Dr. Atsushi Kumanogoh of Osaka University and Drs. Masahisa Hattori and Wataru Suda of The University of Tokyo.

(6) Nucleic acids and autoimmunity

There is increasing evidence that strongly indicates that RNA and DNA sensors of the innate immune system are primary contributors to autoimmune disease pathogenesis. It remains, however, unclear which RNA and/or DNA mediate disease development. During a course of our collaboration with a pharmaceutical company to screen TLR antagonist, we identified a low molecular RNA that strongly activates the immune system via TLR7 and whose contribution to autoimmunity has been known. As such, we are focusing on the role of this RNA and its mechanism of activation of TLR in cooperation with other host cell-derived factors. We are also analyzing the contribution of this RNA to autoimmunity by genetically engineered mice for this RNA and are aiming at development of a compound that interferes with the function of this RNA for therapeutic purpose.

(7) CLR family of innate immune receptors in the regulation of tumor growth and metastasis

The eradication of tumor cells requires communication to and signaling by cells of the immune system. While natural killer (NK) cells are essential tumor-killing effector cells of the innate immune system, little was known about whether or how other immune cells recognize tumor cells to assist NK cells. We found that Dectin-1, a C-type lectin receptor (CLR) family of innate receptors, expressed on dendritic cells and macrophages is critical to NK-mediated killing of tumor cells that express N-glycan structures at high levels. Receptor recognition of these tumor cells causes the activation of IRF5 and downstream gene induction for the full-blown tumoricidal activity of NK cells. Consistent with this, we found mice genetically deficient in either Dectin-1 or IRF5 to show exacerbated in vivo tumor growth (Elife ;3:e04177. doi: 10.7554/eLife.04177, 2014). Further, we found that Dectin-2, another CLR family member, is critical for the suppression of liver metastasis of cancer cells. Dectin-2 functions in resident macrophages in the liver, known as Kupffer cells, to mediate the uptake and clearance of cancer cells. Interestingly, Kupffer cells are selectively endowed with Dectin-2-dependent phagocytotic activity, with neither bone marrow-derived macrophages nor alveolar macrophages able to mediate these effects. Concordantly, subcutaneous primary tumor growth and lung metastasis are not affected by the absence of Dectin-2. In addition, macrophage C-type lectin (MCL) that forms a complex with Dectin-2 also contributes to the suppression of liver metastasis, highlighting the hitherto poorly understood mechanism of Kupffer cell-mediated control of metastasis that is mediated by the CLR innate receptor family (Proc Natl Acad Sci U S A., 113, 4097-14102, 2016). Additional studies are in progress to gain further mechanistic insights on the CLR family-mediated anti-tumor immune responses and to provide new means with which to control tumors by harnessing these receptors. This work is a collaboration with Dr. Yuichiro Iwakura of Tokyo University of Science, Dr. Shinobu Saijyo of Chiba University and Dr. Sho Yamazaki of Kyusyu University.

4. Publications

Briefly, we published ca. 300 papers in the past years. These include one paper in eLife, 24 papers in Nature, 15 papers in Science, 15 papers in Cell, and 38 papers in Proc. Natl. Acad. Sci. USA. In addition, 65 papers were published in the sister journals of Nature, Science and Cell.

Page Top